No Longer Chasing Serotypes: Three Shared Proteins Advance a Broad-Spectrum Pneumococcal Vaccine

Streptococcus pneumoniae can cause pneumonia, sepsis, and meningitis. The challenge lies not only in the severity of these diseases, but also in the bacterium’s more than 100 serotypes. Although current vaccines have substantially reduced invasive infections caused by specific types, their scope of protection remains limited to the types included in their formulations; as vaccine-suppressed strains decline, types not covered by the vaccines may fill the ecological niche.

A study published in *Science Advances* and highlighted by *Nature* shifted the focus from the variable capsule to proteins shared by different strains of Streptococcus pneumoniae. The research team screened for highly conserved antigens, hoping to generate immune responses that would not need to recognize each serotype individually and could also protect against strains not covered by current vaccines, offering a different route toward a “broad-spectrum” pneumococcal vaccine.

The vaccine candidate consists of three components and originated from a reverse-vaccinology process developed by a University of Liverpool team. The researchers first analyzed genomic and computational data from clinical samples, then selected antigens and progressively validated them through in vitro functional assays and animal infection models. According to university materials, the design mobilizes both antibody and cell-mediated immunity; the latest study adds preclinical evidence of cross-serotype protection.

The related technology is being advanced by ReNewVax, a University of Liverpool spinout, under the product code RVX-001. The company says the selected antigens are highly conserved across Streptococcus pneumoniae serotypes and that the recombinant proteins can be produced using Escherichia coli. If subsequent studies confirm feasibility, the manufacturing process could be easier to scale than that of conjugate vaccines that continually add capsular types, and it could also reduce costs. However, these manufacturing and accessibility advantages remain expectations of the developer.

The value of a broad-spectrum vaccine extends beyond expanding a list of serotypes. If immune pressure is no longer concentrated on a small number of capsular types, it could theoretically reduce disease gaps caused by serotype replacement and decrease infections and antibiotic use. However, proteins being “conserved” across strains does not necessarily mean they will produce consistent and durable protection across populations, and responses may also differ among children, older adults, and people with weaker immune function.

Key hurdles remain before the vaccine can be administered in practice. Currently available public data consist mainly of animal efficacy studies and ex vivo human immune research; there are not yet any data on human safety, dosage, durability of immunity, or clinical protective efficacy. The University of Liverpool currently says RVX-001 is expected to enter clinical trials in 2027. This is later than the 2025 timeline proposed in 2022, indicating that preclinical and funding preparations are still underway.

ReNewVax has so far secured approximately £2.6 million in seed funding and is seeking £15 million in Series A financing to support early clinical development. In other words, this study moves cross-type protection one step forward from a vaccine-design concept, but it has not yet demonstrated that the term “universal” applies in humans. The first trials must still begin by answering questions about safety, tolerability, and whether the vaccine can reliably elicit the intended immune response.